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Age	(years)	 IORT+	 IORT-	 	 p-value	 	
N	 21	 25	 	 	 	
Mean	 51.381	 60.2	 	 	 	
Sd	 10.84	 11.453	 	 0.011	 	
	 	 	 	 	 	
Tumour	
Size	(mm)	 IORT+	 IORT-	 	 	 	
N	 21	 25	 	 	 	
Mean	 26	 27.84	 	 	 	
Sd	 11.6276	 9.5029	 	 0.558	 	
	 	 	 	 	 	
Grading	 G1	 G2	 G3	 	 	
IORT+	 0	 13	 8	 	 	
IORT-	 1	 14	 10	 1	
Fishers	
Exact	
	 	 	 	 	 	
Node		 Pos	 Neg	 	 	 	
IORT+	 14	 7	 	 	 	
IORT-	 16	 9	 	 1	
Fishers	
Exact	
	 	 	 	 	 	
pCR	 Pos	 Neg	 	 	 	
IORT+	 4	 17	 	 	 	
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5-year K-M estimates: TARGIT 95.2% EBRT 88% p=0.316
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5-year K-M estimates: TARGIT 0% EBRT 21% p=0.028



































25 24 23 20 11 3EBRT
21 21 21 21 13 0TARGIT
Number at risk




5-year K-M estimates: TARGIT 0% EBRT 4% p=0.350
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5-year K-M estimates: TARGIT 0% EBRT 16.0% p=0.047
Non-Breast-Cancer Deaths - HER2 Neg
radiotherapy	in	the	course	of	breast	conserving	therapy	and	has	been	found	non-inferior	to	
external	whole	breast	irradiation	in	selected	patients	in	a	risk	adapted	approach	in	the	
TARGIT	A	trial	1.	There	has	been	concern	regarding	a	possible	higher	rate	of	breast	fibrosis	
found	with	TARGIT-IORT.	An	analysis	of	the	TARGIT	A	population	demonstrated	a		rate	of	
breast	fibrosis	within	the	range	seen	with	EBRT	alone	13.	In	previous	studies	of	our	group	we	
found	that	adapting	this	approach	among	patients	who	were	undergoing	breast	conserving	
therapy	after	neoadjuvant	systemic	therapy	does	not	compromise	cosmetic	outcome	14,		
does	not	interfere	with	pathological	evaluation	of	the	margins	and	does	not	alter	re-excision	
rates	15.		
Patients	who	are	candidates	for	neoadjuvant	therapy	are	generally	at	high	risk	of	local	and	
distant	relapse	and	of	death	from	breast	cancer	16	17.	A	retrospective	analysis	using	a	
different	technique	of	intraoperative	radiotherapy	–	Intraoperative	Electron	radiotherapy	
(IOERT)	-	compared	83	patients	receiving	IOERT	after	neoadjuvant	therapy	with	a	group	of	
26	patients	receiving	conventional	EBRT	boost	and	found	a	trend	for	superiority	for	IOERT	9.		
	
In	the	non-randomized	retrospective	cohort	analysis	presented	here	we	compared	
intraoperative	tumour	bed	boost	with	a	50kV	X-ray	device	with	an	external	boost	among	
patients	undergoing	breast	conserving	surgery	after	neoadjuvant	chemotherapy	including	
only	patients	with	hormone	receptor	positive	HER2	negative	tumours.	All	patients	received	
external	beam	whole	breast	irradiation.	The	rationale	for	our	investigation	was	based	on	our	
findings	regarding	the	whole	cohort.	In	this	previous	analysis	patients	receiving	their	boost	
as	TARGIT-IORT	had	a	statistically	significant	better	overall	survival	11.	Based	on	the	
hypothesis	that	this	difference	might	be	attributed	to	the	subset	of	patients	with	the	worst	
prognosis	at	baseline	we	had	then	decided	to	look	at	patients	with	triple	negative	and	HER2	
positive	tumours	specifically.	In	this	analysis	neither	DFS	nor	OS	differed	significantly	
between	patients	receiving	an	external	boost	and	patients	receiving	TARGIT-IORT	although	
trends	favoured	TARGIT-IORT	12.	These	findings	triggered	the	analysis	presented	here	
assuming	the	effect	in	the	unselected	cohort	must	have	been	driven	by	the	hormone	
receptor	positive	HER2	negative	subgroup.		
The	comparator	groups	were	well	balanced	with	age	being	the	only	significant	difference.	Of	
course	this	difference	has	to	be	addressed	regarding	the	significant	difference	in	overall	
survival	driven	by	non-breast-cancer	mortality.	Considering	the	median	follow	up	of	49	
months	the	mean	age	of	51	years	in	the	TARGIT	group	and	60	years	in	the	EBRT	group	will	
probably	not	have	influenced	the	non-breast-cancer	mortality	difference	significantly	since	
the	short	time	survival	probability	is	0.99769726	for	a	female	aged	51	in	Germany	and	of	
0.99471509	for	the	age	of	60	respectively	(www-genesis.destatis.de).		
	
Both	cohorts	received	the	same	chemotherapy	schedules	and	achieved	similar	proportions	
of	pathological	complete	response.	Endocrine	therapies	according	to	menopausal	status	
were	the	same	for	both	groups.	However,	even	though	we	found	no	significant	difference	in	
patient	characteristics	between	the	two	cohorts,	a	selection	bias	cannot	be	excluded	
because	this	was	not	a	randomised	trial.		
In	the	TARGIT-A	study	1	a	trend	for	superior	overall	survival	with	TARGIT-IORT	compared	
with	EBRT	was	observed.	This	was	mainly	attributable	to	reduced	mortality	from	causes	
other	than	breast	cancer.	It	has	been	suggested	that	the	favourable	effects	of	IORT	on	
surgical	wound	fluid	may	result	in	wider	systemic	beneficial	effects	that	may	have	
contributed	to	the	reduced	mortality	seen	in	the	TARGIT-A	trial.	A	non-randomised	
comparison	of	those	patients	in	the	TARGIT-A	trial	who	received	IORT	+	EBRT	versus	those	
who	received	EBRT	found	a	statistically	significant	reduction	in	non-breast-cancer	mortality.	
There	were	no	deaths	from	non-breast	cancer	causes	in	the	IORT+EBRT	group	compared	
with	24	in	the	EBRT	group	0/218	vs	24/892,	log-rank	p	=	0.012	18.	An	explanation	the	authors	
suggested	for	this	phenomenon	was	a	potential	influence	of	immediate	IORT	on	local	
tumour	microenvironment	and	wound	fluid	that	could	get	absorbed	and	cause	systemic	
beneficial	effects.	Tumour	cell	line	experiments	have	shown	that	the	stimulating	effect	of	
wound	fluid	after	lumpectomy	on	breast	cancer	cell	proliferation,	motility	and	invasiveness	
is	abrogated	if	the	patient	receives	IORT	during	the	lumpectomy	19.	An	analysis	of	the	same	
study	group	demonstrated	an	induction	of	miR-223	in	the	peritumoral	breast	tissue	resulting	
in	a	downregulation	of	the	local	expression	of	epidermal	growth	factor	(EGF)	and	a	
decreased	activation	of	epidermal	growth	factor	receptor	(EGFR)	after	IORT	as	a	possible	
explanation	for	this	effect	20.	It	has	also	previously	been	discussed	that	IORT	during	
lumpectomy	may	be	changing	the	systemic	course	of	not	just	breast	cancer	but	also	that	of	
ischemic	heart	disease	for	the	better	21.		Another	explanation	of	the	general	effects	of	
intraoperative	radiotherapy	could	be	a	possible	influence	on	factors	of	tumour	immunology	
such	as	“programmed	death	1”	(PD-1,	ligands	PD-L1	and	PD-L2)	and	“cytotoxic	T-lymphocyte	
antigen	4”	(CTLA-4,	ligands	CD80	und	CD	86)	due	to	the	localized	character	of	the	therapy.	
There	are	signals	that	local	therapies	may	play	a	role	in	the	presentation	of	tumour	cells	as	
antigens	to	the	immune	system	thus	triggering	generalized	immunological	responses.	
Investigations	on	the	use	of	high	focused	ultrasound	applied	to	tumours	for	example	showed	
an	increased	accumulation	of	natural	killer	cells	within	the	tumour	22.		
The	outcome	data	reported	from	our	group	before	11	and	reproduced	in	the	subgroup	
analysis	presented	here	seem	to	support	the	hypothesis	that	the	benefit	of	IORT	may	not	be	
limited	to	a	local	effect	by	simply	avoiding	a	geographic	miss.	The	significantly	better	overall	
survival	in	the	unselected	cohort	as	well	as	in	the	hormone	receptor	positive	HER2	negative	
subgroup	was	driven	by	the	significantly	better	non-breast-cancer	specific	mortality.	As	
mentioned	above	a	similar	effect	was	demonstrated	in	the	TARGIT-A	study	in	the	whole	
study	population	1	as	well	as	in	the	subgroup	of	patients	receiving	whole	breast	irradiation	
after	IORT,	i.e.	receiving	the	same	therapy	as	our	study	population	18.	
	
Due	to	the	retrospective	character	of	our	trial	we	are	recommending	a	cautious	
interpretation	of	these	data,	but	still	our	findings	confirm	that	the	use	of	TARGIT-IORT	as	a	
boost	is	yielding	results	not	worse	than	external	boost	irradiation.	Regarding	the	supposed	
beneficial	effect	of	TARGIT-IORT	on	non-breast-cancer-specific	mortality	more	research	is	
needed.	We	are	planning	a	matched-pairs	analysis	of	our	dataset	of	the	more	than	700	cases	
treated	at	our	institution	with	TARGIT-IORT	as	an	intraoperative	boost	yet	compared	with	
cases	treated	with	an	external	boost	with	a	focus	on	comorbidities	at	baseline	and	non-
breast-cancer-specific	morbidity	and	mortality	and	the	influence	of	tumour	biology.		
Furthermore	the	hypothesis	of	possible	systemic	beneficial	effects	of	IORT	will	be	
prospectively	tested	in	the	randomised	TARGIT-B	trial	comparing	TARGIT-IORT	boost	to	an	
external	boost	in	women	who	are	either	younger	than	45	or	have	a	higher	risk	of	local	
recurrence.	This	trial	is	including	a	stratification	for	the	use	of	neoadjuvant	chemotherapy	
and	planned	subgroup	analyses	regarding	tumour	biology.	We	encourage	active	
participation	in	the	TARGIT-B	trial.		
	
Conclusion	
	
In	a	previous	analysis	we	demonstrated	non-inferior	and	numerically	superior	overall	
survival	attributable	to	a	lower	non-breast-cancer	mortality	for	TARGIT-IORT	during	
lumpectomy	after	neoadjuvant	chemotherapy	as	a	tumour	bed	boost	compared	to	an	
external	beam	radiotherapy	boost	in	an	unselected	population.	In	our	current	analysis	we	
could	show	that	this	difference	is	driven	by	the	hormone	receptor	positive	HER2	negative	
subgroup,	although	we	acknowledge	that	our	results	have	to	be	interpreted	with	caution	
due	to	a	possible	selection	bias,	the	comparatively	small	sample	size	and	a	rather	short	
follow-up	for	a	hormone	receptor	positive	cohort.	These	data	give	further	support	to	the	
inclusion	of	such	patients	in	the	randomised	TARGIT-B	trial	testing	whether	IORT	boost	is	
superior	to	EBRT	boost	and	the	analysis	of	subgroups	based	on	tumour	biology	in	this	trial.	
Furthermore	our	results	are	warranting	further	investigation	on	effects	of	TARGIT-IORT	on	
non-breast-cancer-specific	endpoints.	
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